Penumbra Reports Positive Data for Pulmonary Embolism Treatment

Dow Jones

2025/11/04

By Katherine Hamilton

Penumbra reported positive data for a trial of its treatment for pulmonary embolism.

The use of computer-assisted vacuum thrombectomy resulted in improvements in thrombus burden reduction, heart rate, oxygen requirement and functional outcomes in patients with the blood-clot disorder, Penumbra said.

A significantly higher share of patients treated with CAVT returned to normalization within 48 hours compared to those who weren't treated with it, the Alameda, Calif., company said Monday. They had lower heart rates and were able to walk longer distances following treatment.

The results show CAVT can rapidly and safely improve patient outcomes, Chief Medical Officer James Benenati said. He said the treatment should be considered as a therapeutic option for patients with acute intermediate to high risk pulmonary embolism.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

November 03, 2025 15:26 ET (20:26 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2580247694"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580247694\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580247694?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 04:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580247694","market":"nz","top_or_hot":-1,"title":"Penumbra Reports Positive Data for Pulmonary Embolism Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Penumbra reported positive data for a trial of its treatment for pulmonary embolism. \n</p>\n<p>\n  The use of computer-assisted vacuum thrombectomy resulted in improvements in thrombus burden reduction, heart rate, oxygen requirement and functional outcomes in patients with the blood-clot disorder, Penumbra said. \n</p>\n<p>\n  A significantly higher share of patients treated with CAVT returned to normalization within 48 hours compared to those who weren't treated with it, the Alameda, Calif., company said Monday. They had lower heart rates and were able to walk longer distances following treatment. \n</p>\n<p>\n  The results show CAVT can rapidly and safely improve patient outcomes, Chief Medical Officer James Benenati said. He said the treatment should be considered as a therapeutic option for patients with acute intermediate to high risk pulmonary embolism. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 03, 2025 15:26 ET (20:26 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Penumbra Reports Positive Data for Pulmonary Embolism Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPenumbra Reports Positive Data for Pulmonary Embolism Treatment\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-11-04 04:26</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Penumbra reported positive data for a trial of its treatment for pulmonary embolism. \n</p>\n<p>\n  The use of computer-assisted vacuum thrombectomy resulted in improvements in thrombus burden reduction, heart rate, oxygen requirement and functional outcomes in patients with the blood-clot disorder, Penumbra said. \n</p>\n<p>\n  A significantly higher share of patients treated with CAVT returned to normalization within 48 hours compared to those who weren't treated with it, the Alameda, Calif., company said Monday. They had lower heart rates and were able to walk longer distances following treatment. \n</p>\n<p>\n  The results show CAVT can rapidly and safely improve patient outcomes, Chief Medical Officer James Benenati said. He said the treatment should be considered as a therapeutic option for patients with acute intermediate to high risk pulmonary embolism. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 03, 2025 15:26 ET (20:26 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4548","symbol_name":"巴美列捷福持倉","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2580247694","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580247694","pubTimestamp":1762201560,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Penumbra reported positive data for a trial of its treatment for pulmonary embolism.The use of computer-assisted vacuum thrombectomy resulted in improvements in thrombus burden reduction, heart rate, oxygen requirement and functional outcomes in patients with the blood-clot disorder, Penumbra said.A significantly higher share of patients treated with CAVT returned to normalization within 48 hours compared to those who weren't treated with it, the Alameda, Calif., company said Monday. They had lower heart rates and were able to walk longer distances following treatment.The results show CAVT can rapidly and safely improve patient outcomes, Chief Medical Officer James Benenati said. He said the treatment should be considered as a therapeutic option for patients with acute intermediate to high risk pulmonary embolism.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4548":"巴美列捷福持仓","BK4082":"医疗保健设备","PEN":"Penumbra Inc"},"translate_title":"Penumbra报告肺栓塞治疗的积极数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PEN":1.5},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Penumbra reported positive data for a trial of its treatment for pulmonary embolism. \n\n\n  The use of computer-assisted vacuum thrombectomy resulted in improvements in thrombus burden reduction, heart rate, oxygen requirement and functional outcomes in patients with the blood-clot disorder, Penumbra said. \n\n\n  A significantly higher share of patients treated with CAVT returned to normalization within 48 hours compared to those who weren't treated with it, the Alameda, Calif., company said Monday. They had lower heart rates and were able to walk longer distances following treatment. \n\n\n  The results show CAVT can rapidly and safely improve patient outcomes, Chief Medical Officer James Benenati said. He said the treatment should be considered as a therapeutic option for patients with acute intermediate to high risk pulmonary embolism. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 03, 2025 15:26 ET (20:26 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}